Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates

Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01856-17. doi: 10.1128/AAC.01856-17. Print 2018 Jan.

Abstract

A total of 10,451 contemporary (2016) Enterobacteriaceae isolates from 84 U.S. medical centers and 116 metallo-β-lactamase- and/or OXA-48-like-producing Enterobacteriaceae isolates from other countries were tested against aztreonam-avibactam and comparators. All U.S. isolates were inhibited at aztreonam-avibactam MICs of ≤8 μg/ml (MIC50, ≤0.03 μg/ml; MIC90, 0.12 μg/ml), including Klebsiella pneumoniae carbapenemase-producing isolates (n = 102; MIC50, 0.25 μg/ml; MIC90, 0.5 μg/ml), multidrug-resistant isolates (n = 876; MIC50, 0.06 μg/ml; MIC90, 0.25 μg/ml), and extensively drug-resistant isolates (n = 111; MIC50, 0.12 μg/ml; MIC90, 0.5 μg/ml). The highest aztreonam-avibactam MIC value among ex-U.S. isolates was 4 μg/ml.

Keywords: CRE; KPC; NDM-1; OXA-48; carbapenem-resistant Enterobacteriaceae; metallo-β-lactamase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Azabicyclo Compounds / pharmacology*
  • Aztreonam / pharmacology*
  • Drug Resistance, Multiple, Bacterial / drug effects
  • Enterobacteriaceae / drug effects*
  • Humans
  • Klebsiella pneumoniae / drug effects
  • Microbial Sensitivity Tests / methods
  • beta-Lactamases / pharmacology

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • avibactam
  • beta-Lactamases
  • Aztreonam